Analysts Issue Forecasts for MBX Biosciences FY2026 Earnings

MBX Biosciences, Inc. (NASDAQ:MBX – Free Report) – Investment analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of MBX Biosciences in a report released on Thursday, November 12th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($3.13) per share for the year. HC Wainwright has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for MBX Biosciences’ current full-year earnings is ($3.42) per share. HC Wainwright also issued estimates for MBX Biosciences’ Q4 2026 earnings at ($1.00) EPS, Q1 2027 earnings at ($1.01) EPS, Q2 2027 earnings at ($1.08) EPS, Q3 2027 earnings at ($1.12) EPS, Q4 2027 earnings at ($1.16) EPS and FY2027 earnings at ($4.37) EPS.

Other equities research analysts also recently issued reports about the company. Mizuho increased their price target on MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Wall Street Zen cut shares of MBX Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Stifel Nicolaus boosted their price objective on shares of MBX Biosciences from $70.00 to $84.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Truist Financial upped their price objective on shares of MBX Biosciences from $70.00 to $88.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, UBS Group restated a “buy” rating on shares of MBX Biosciences in a research note on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, MBX Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $87.30.

Read Our Latest Stock Analysis on MBX

MBX Biosciences Price Performance

NASDAQ:MBX opened at $53.12 on Monday. MBX Biosciences has a 12-month low of $24.68 and a 12-month high of $72.64. The stock’s 50 day simple moving average is $55.61 and its 200-day simple moving average is $46.48.

MBX Biosciences (NASDAQ:MBX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.49).

Institutional Investors Weigh In On MBX Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of MBX. Bellevue Group AG acquired a new stake in shares of MBX Biosciences in the third quarter valued at about $131,000. Cetera Investment Advisers purchased a new stake in MBX Biosciences during the third quarter worth about $257,000. HighVista Strategies LLC boosted its holdings in MBX Biosciences by 301.5% during the third quarter. HighVista Strategies LLC now owns 46,709 shares of the company’s stock worth $2,738,000 after buying an additional 35,075 shares in the last quarter. First Trust Advisors LP purchased a new stake in MBX Biosciences during the third quarter worth about $1,169,000. Finally, Voya Investment Management LLC grew its position in MBX Biosciences by 117.8% during the third quarter. Voya Investment Management LLC now owns 56,914 shares of the company’s stock worth $3,336,000 after buying an additional 30,782 shares during the period.

Insider Buying and Selling at MBX Biosciences

In related news, CEO Steven Hoerter sold 4,893 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $54.82, for a total transaction of $268,234.26. Following the transaction, the chief executive officer owned 78,045 shares of the company’s stock, valued at $4,278,426.90. This represents a 5.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 31.09% of the stock is currently owned by company insiders.

Latest MBX Biosciences News

Here’s some of the latest news about MBX:

  • Positive Sentiment: HC Wainwright reiterated a Buy rating and set a $90 price target, well above MBX’s recent trading level. Its FY2026 loss estimate of $3.13 per share is also slightly less severe than the cited consensus forecast. Brokers Issue Forecasts for MBX Biosciences FY2026 Earnings
  • Negative Sentiment: Director Steven Hoerter sold 4,893 shares, a transaction investors may view as a modest negative signal. The available report does not specify the sale proceeds. MBX Biosciences Stock: Insider Steven Hoerter Sells 4,893 Shares
  • Negative Sentiment: HC Wainwright’s estimates still project losses, including a $4.37-per-share loss for FY2027—larger than its $3.13-per-share FY2026 forecast. That outlook underscores MBX’s ongoing cash-burning development-stage profile.

MBX Biosciences Company Profile

(Get Free Report)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.

Featured Articles

Earnings History and Estimates for MBX Biosciences (NASDAQ:MBX)

Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.